| Patients with multiple sclerosis (MS) treated with cladribine tablets (CladT) are not at higher risk of developing severe COVID-19. |
| CladT treatment does not impact the production of anti-SARS-CoV-2 antibodies after COVID-19 vaccination. |
| CladT treatment does not increase the risk of breakthrough COVID-19 infection. |
| CladT’s transient effect on innate immune cells likely contributes to maintaining an adequate first line of defense against the SARS-CoV-2 virus. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.